Drug Approval | February 22, 2022
UK MHRA approves Marksans All in One oral solution
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
The transaction as well as the open offer is expected to be completed by June this year.
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
To be marketed by Strides Pharma Inc. in the US market
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector
Subscribe To Our Newsletter & Stay Updated
